By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
A short-acting 2 adrenergic receptor agonist used to treat asthma and chronic obstructive pulmonary disease is levosalbutamol, often known as levalbuterol (COPD).
Levosalbutamol is thought to have a superior safety profile due to its more selective binding to 2 receptors (mainly in the lungs) versus 1 receptor, while evidence is unclear on the effectiveness of levosalbutamol over salbutamol or salbutamol-levosalbutamol combinations (primarily in the heart muscle).
The medication is the (R)-()-enantiomer of its salbutamol prototype. It is offered in various nations in generic forms made by drug manufacturers like Cipla, Teva, and Dey, among others.
Due to its bronchodilator effects, levosalbutamol is indicated for the treatment of asthma and COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease).
Similar to other bronchodilators, it shortens or reverses an acute “attack” of shortness of breath or trouble breathing by relaxing the smooth muscle in the bronchial tubes. It is not recommended as a treatment for chronic bronchial constriction, in contrast to several bronchodilators with a later onset of action.
Levosalbutamol is typically well tolerated. Muscle cramps, gastrointestinal discomfort, and an increased heart rate are typical of moderate adverse effects (including heartburn and diarrhea).
Particular overdose symptoms include collapsing into a seizure, chest pain (possible heart attack precursor), a rapid, pounding heartbeat that may raise blood pressure (hypertension), irregular heartbeat that may paradoxically lower blood pressure (hypotension), nervousness and tremor, headache, nausea/vomiting, dizziness, dry mouth, and insomnia.
Rarer side effects could be an allergic reaction that could be hazardous. Itching, rash, or hives on the skin; angioedema of any area of the face or throat (which can cause voice hoarseness); paradoxical bronchospasm (shortness of breath and difficulty breathing); or swelling of the extremities are a few of these.
Adenylate cyclase is activated and the intracellular concentration of 3′,5′-cyclic adenosine monophosphate increases when the 2 adrenergic receptors on airway smooth muscle are activated (cyclic AMP).
When cyclic AMP levels rise, protein kinase A is also activated. This lowers intracellular calcium concentrations and inhibits myosin phosphorylation, which causes muscles to relax.
The Global LEVOSALBUTAMOL market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
One of the top companies in the pharmaceutical sector, Anglo-French Drugs & Industries Limited, has announced the launch of new medicines in the AFD-PULMO-LS division. Levosalbutamol, Ambroxol, and Guaiphenesin are the three primary compounds found in cough syrup.
Excellent bronchodilator levosalbutamol safely and effectively opens the airways. A potent mucolytic, ambroxol dissolves phlegm, expels it from the lungs, and guards against the formation of new phlegm. medication that is mucoactive: guaiphenesin.
It improves bronchial secretion volume and lowers mucus viscosity, which helps to release mucus in the airways and facilitates expectoration, or coughing up mucus.
Additionally, AFD-PULMO-LS comes in a PET bottle that is unbreakable, has a measuring cap that is calibrated, has a great flavor (raspberry), and is sugar-free, making it suitable for diabetic people.
